Outcomes for COPD pharmacological trials: from lung function to biomarkers
Top Cited Papers
Open Access
- 31 January 2008
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 31 (2) , 416-469
- https://doi.org/10.1183/09031936.00099306
Abstract
The American Thoracic Society/European Respiratory Society jointly created a Task Force on “Outcomes for COPD pharmacological trials: from lung function to biomarkers” to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations.Keywords
This publication has 527 references indexed in Scilit:
- Pulse oximetryIntensive Care Medicine, 2004
- Economic valuation of informal careThe European Journal of Health Economics, 2004
- Coronary angiography from the radial artery – experience, complications and limitationsInternational Journal of Cardiology, 1998
- The friction cost method for measuring indirect costs of diseaseJournal of Health Economics, 1995
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994
- Within-day variation of bioelectrical resistance measurements in patients with chronic obstructive pulmonary diseaseClinical Nutrition, 1990
- Measurement of health statusControlled Clinical Trials, 1989
- How should we measure function in patients with chronic heart and lung disease?Journal of Chronic Diseases, 1985
- Validity of a quality of well-being scale as an outcome measure in chronic obstructive pulmonary diseaseJournal of Chronic Diseases, 1984
- LONG TERM DOMICILIARY OXYGEN THERAPY IN CHRONIC HYPOXIC COR PULMONALE COMPLICATING CHRONIC BRONCHITIS AND EMPHYSEMAThe Lancet, 1981